These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34227209)

  • 1. PEGylated Oligothioetheramide Prodrugs Activated by Host Serum Proteases.
    Artim CM; Kunala M; O'Leary MK; Alabi CA
    Chembiochem; 2021 Sep; 22(17):2697-2702. PubMed ID: 34227209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Readily adaptable release kinetics of prodrugs using protease-dependent reversible PEGylation.
    Böttger R; Knappe D; Hoffmann R
    J Control Release; 2016 May; 230():88-94. PubMed ID: 27067364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled systemic release of therapeutic peptides from PEGylated prodrugs by serum proteases.
    Nollmann FI; Goldbach T; Berthold N; Hoffmann R
    Angew Chem Int Ed Engl; 2013 Jul; 52(29):7597-9. PubMed ID: 23766125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a PEGylated Antimicrobial Prodrug with Species-Specific Activation.
    O'Leary MK; Chen SS; Westblade LF; Alabi CA
    Biomacromolecules; 2021 Feb; 22(2):984-992. PubMed ID: 33428376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Composition on Antibacterial Activity of Sequence-Defined Cationic Oligothioetheramides.
    Artim CM; Phan NN; Alabi CA
    ACS Infect Dis; 2018 Aug; 4(8):1257-1263. PubMed ID: 29750860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Properties and Pharmacokinetics of Temporarily PEGylated Onc72 Prodrugs.
    Mohammed GK; Böttger R; Krizsan A; Volke D; Mötzing M; Li SD; Knappe D; Hoffmann R
    Adv Healthc Mater; 2023 Apr; 12(11):e2202368. PubMed ID: 36631971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting.
    Stefan N; Zimmermann M; Simon M; Zangemeister-Wittke U; Plückthun A
    Bioconjug Chem; 2014 Dec; 25(12):2144-56. PubMed ID: 25350699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEGylated prodrugs of antidiabetic peptides amylin and GLP-1.
    Böttger R; Knappe D; Hoffmann R
    J Control Release; 2018 Dec; 292():58-66. PubMed ID: 29729352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells.
    Kelly GJ; Kia AF; Hassan F; O'Grady S; Morgan MP; Creaven BS; McClean S; Harmey JH; Devocelle M
    Org Biomol Chem; 2016 Oct; 14(39):9278-9286. PubMed ID: 27722734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of Antibacterial Activity to Backbone Sequence in Constitutionally Isomeric OligoTEAs.
    Hoff EA; Artim CM; Brown JS; Alabi CA
    Macromol Biosci; 2018 Nov; 18(11):e1800241. PubMed ID: 30238615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hypoxia-activated antibacterial prodrug.
    Yeoh YQ; Horsley JR; Polyak SW; Abell AD
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127140. PubMed ID: 32247730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Disease-Associated Enzymes to Activate Antimicrobial Peptide Prodrugs.
    Forde ÉB; Kelly G; Makki H; Al-Sharshahi Z; Fitzgerald-Hughes D; Devocelle M
    Methods Mol Biol; 2017; 1548():359-368. PubMed ID: 28013518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Releasable PEGylation of proteins with customized linkers.
    Filpula D; Zhao H
    Adv Drug Deliv Rev; 2008 Jan; 60(1):29-49. PubMed ID: 17884239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection.
    Bhawsar S; Kale R; Deshpande P; Yeole R; Bhagwat S; Patel M
    Bioorg Med Chem Lett; 2021 Dec; 54():128432. PubMed ID: 34757217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Action of antimicrobial peptides and their prodrugs on model and biological membranes.
    Forde É; Shafiy G; Fitzgerald-Hughes D; Strömstedt AA; Devocelle M
    J Pept Sci; 2018 Jul; 24(7):e3086. PubMed ID: 29799150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of mutual azo prodrugs of anti-inflammatory agents and peptides facilitated by α-aminoisobutyric acid.
    Kennedy DA; Vembu N; Fronczek FR; Devocelle M
    J Org Chem; 2011 Dec; 76(23):9641-7. PubMed ID: 22026631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers.
    Gupta D; Gupta SV; Lee KD; Amidon GL
    Mol Pharm; 2009; 6(5):1604-11. PubMed ID: 19566080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carvacrol prodrugs as novel antimicrobial agents.
    Marinelli L; Fornasari E; Eusepi P; Ciulla M; Genovese S; Epifano F; Fiorito S; Turkez H; Örtücü S; Mingoia M; Simoni S; Pugnaloni A; Di Stefano A; Cacciatore I
    Eur J Med Chem; 2019 Sep; 178():515-529. PubMed ID: 31207463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay.
    Gunaseelan S; Debrah O; Wan L; Leibowitz MJ; Rabson AB; Stein S; Sinko PJ
    Bioconjug Chem; 2004; 15(6):1322-33. PubMed ID: 15546199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of novel nitroreductase enzyme-activated nitric oxide prodrugs to site-specifically kill bacteria.
    Hibbard HAJ; Reynolds MM
    Bioorg Chem; 2019 Dec; 93():103318. PubMed ID: 31586703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.